Free Trial

Gilead Sciences (GILD) Competitors

Gilead Sciences logo
$113.12 +2.06 (+1.85%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GILD vs. LGND, MRNA, REGN, VIR, VRTX, ABBV, MRK, PFE, AMGN, and ALNY

Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Amgen (AMGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "medical" sector.

Gilead Sciences vs. Its Competitors

Gilead Sciences (NASDAQ:GILD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Gilead Sciences has a net margin of 20.76% compared to Ligand Pharmaceuticals' net margin of -73.07%. Gilead Sciences' return on equity of 51.93% beat Ligand Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences20.76% 51.93% 17.40%
Ligand Pharmaceuticals -73.07%-7.83%-6.92%

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$28.75B4.80$480M$4.7523.38
Ligand Pharmaceuticals$167.13M13.29-$4.03M-$7.12-16.17

In the previous week, Gilead Sciences had 44 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 50 mentions for Gilead Sciences and 6 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.24 beat Ligand Pharmaceuticals' score of 0.72 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
38 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Ligand Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gilead Sciences currently has a consensus price target of $111.38, suggesting a potential upside of 0.29%. Ligand Pharmaceuticals has a consensus price target of $147.17, suggesting a potential upside of 27.84%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
9 Hold rating(s)
14 Buy rating(s)
3 Strong Buy rating(s)
2.77
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Gilead Sciences has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Summary

Gilead Sciences beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GILD vs. The Competition

MetricGilead SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$139.05B$2.88B$5.50B$8.94B
Dividend Yield2.83%2.45%5.25%4.04%
P/E Ratio23.3820.8026.9720.11
Price / Sales4.80287.03426.02119.76
Price / Cash16.2741.1936.8257.86
Price / Book7.197.487.985.56
Net Income$480M-$55.04M$3.16B$248.40M
7 Day Performance-0.40%2.44%2.36%4.67%
1 Month Performance-1.72%1.90%2.15%6.64%
1 Year Performance63.90%4.35%33.78%21.31%

Gilead Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
4.8345 of 5 stars
$111.06
-0.6%
$111.38
+0.3%
+64.4%$139.05B$28.75B23.3817,600Positive News
LGND
Ligand Pharmaceuticals
4.7539 of 5 stars
$113.93
-0.6%
$146.14
+28.3%
+32.5%$2.20B$167.13M-16.0080
MRNA
Moderna
4.3741 of 5 stars
$30.15
-1.1%
$46.61
+54.6%
-72.1%$11.66B$3.24B-3.455,800Gap Up
REGN
Regeneron Pharmaceuticals
4.9372 of 5 stars
$537.20
-1.9%
$813.57
+51.4%
-47.9%$58.02B$14.20B13.6815,106Trending News
Analyst Revision
VIR
Vir Biotechnology
3.1902 of 5 stars
$5.30
-2.1%
$32.86
+520.5%
-37.1%$731.97M$14.30M-1.25580
VRTX
Vertex Pharmaceuticals
4.345 of 5 stars
$459.16
-0.1%
$511.62
+11.4%
-3.2%$117.91B$11.10B-117.136,100Positive News
ABBV
AbbVie
4.9417 of 5 stars
$187.35
-1.0%
$211.29
+12.8%
+13.9%$330.93B$56.33B79.7255,000Trending News
Analyst Revision
MRK
Merck & Co., Inc.
4.9985 of 5 stars
$80.99
+0.1%
$109.19
+34.8%
-35.3%$203.37B$64.17B11.7975,000Positive News
PFE
Pfizer
4.9739 of 5 stars
$25.21
-0.7%
$28.55
+13.3%
-8.3%$143.30B$63.63B18.2681,000Trending News
AMGN
Amgen
4.2637 of 5 stars
$292.69
-1.9%
$307.82
+5.2%
-4.6%$157.46B$33.42B26.7228,000Positive News
ALNY
Alnylam Pharmaceuticals
4.1206 of 5 stars
$322.21
-2.9%
$341.91
+6.1%
+24.5%$42.08B$2.25B-154.422,230Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:GILD) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners